2型糖尿病缓解策略的试点研究:一项随机对照试验的结果
这项随机、平行、开放标签试点试验纳入83例病程不超过3年的2型糖尿病患者,比较8周或16周强化代谢干预与标准糖尿病照护。8周时8周组50.0% vs 对照组3.6%达到治疗中血糖正常(RR 14.0,95%CI 1.97至99.38),16周时16周组70.4% vs 对照组3.6%(RR 19.7,95%CI 2.83至137.13)。干预结束12周后,8周组21.4% vs 对照组10.7%(RR 2.00,95%CI 0.55至7.22)、16周组40.7% vs 对照组14.3%(RR 2.85,95%CI 1.03至7.87)达到完全或部分糖尿病缓解的糖化血红蛋白标准。
要点
- 8周强化干预组50.0% vs 对照组3.6%达到治疗中血糖正常(RR 14.0,95%CI 1.97至99.38)。
- 16周强化干预组70.4% vs 对照组3.6%达到治疗中血糖正常(RR 19.7,95%CI 2.83至137.13)。
- 干预结束12周后16周组40.7% vs 对照组14.3%达到完全或部分缓解的糖化血红蛋白标准(RR 2.85,95%CI 1.03至7.87)。
核心结论
- 短期强化生活方式和药物治疗可实现治疗中血糖正常并促进持续体重下降。
- 该策略也可能实现长期无药糖尿病缓解,并强烈支持开展针对缓解的新型医学方案研究。
研究设计与样本
- 随机、平行、开放标签试点试验,83例参与者随访52周。
- 参与者为病程不超过3年的2型糖尿病患者,在门诊照护环境中进行。
- 参与者随机分为8周强化代谢干预组、16周强化代谢干预组或标准糖尿病照护组。
主要发现
- 8周时,8周干预组50.0% vs 对照组3.6%达到治疗中血糖正常(RR 14.0,95%CI 1.97至99.38)。
- 16周时,16周干预组70.4% vs 对照组3.6%达到治疗中血糖正常(RR 19.7,95%CI 2.83至137.13)。
- 干预完成12周后,8周组21.4% vs 对照组10.7%达到完全或部分糖尿病缓解的糖化血红蛋白标准(RR 2.00,95%CI 0.55至7.22)。
- 干预完成12周后,16周组40.7% vs 对照组14.3%达到完全或部分糖尿病缓解的糖化血红蛋白标准(RR 2.85,95%CI 1.03至7.87)。
关键数值与推荐
- 强化干预期间以减重和血糖正常为目标,采用生活方式干预及二甲双胍、阿卡波糖和甘精胰岛素治疗。
- 干预组随后停用糖尿病药物,并随访高血糖复发情况。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Medical strategies targeting remission of type 2 diabetes have not been systematically studied. OBJECTIVE: This trial assessed the feasibility, safety, and potential to induce remission of a short-term intensive metabolic strategy. DESIGN: A randomized, parallel, open-label pilot trial with 83 participants followed for 52 weeks. SETTING: Ambulatory care. PARTICIPANTS: Patients with type 2 diabetes of up to 3 years in duration. INTERVENTIONS: Participants were randomized to: (1) an 8-week intensive metabolic intervention, (2) a 16-week intensive metabolic intervention, or (3) standard diabetes care. During the intensive intervention period, weight loss and normoglycemia were targeted using lifestyle approaches and treatment with metformin, acarbose, and insulin glargine. Diabetes drugs were then discontinued in the intervention groups and participants were followed for hyperglycemic relapse. PRIMARY OUTCOME: On-treatment normoglycemia. RESULTS: At 8 weeks, 50.0% of the 8-week intervention group vs 3.6% of controls achieved normoglycemia on therapy [relative risk (RR), 14.0; 95% confidence interval (CI), 1.97 to 99.38), and at 16 weeks, these percentages were 70.4% in the 16-week group and 3.6% in controls (RR, 19.7; 95% CI, 2.83 to 137.13). Twelve weeks after completion of the intervention, 21.4% of the 8-week group compared with 10.7% of controls (RR, 2.00; 95% CI, 0.55 to 7.22) and 40.7% of the 16-week group compared with 14.3% of controls (RR, 2.85; 95% CI, 1.03 to 7.87) met hemoglobin A1C criteria for complete or partial diabetes remission. CONCLUSIONS: A short course of intensive lifestyle and drug therapy achieves on-treatment normoglycemia and promotes sustained weight loss. It may also achieve prolonged, drug-free diabetes remission and strongly supports ongoing studies of novel medical regimens targeting remission.
引用
- McInnes N, Smith A, Otto R, et al. Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. J Clin Endocrinol Metab. 2017. PMID: 28324049. doi:10.1210/jc.2016-3373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。